Attention: open in a new window. PDFPrint option in slimbox / lytebox? (info)E-mail

ICAV has developed a international network of over 500 scientists in all areas of anti-viral drug discovery. ICAV draws lead compounds for development from this multi-disciplinary network composed of leading scientists and academics.


The ICAV scientific network consists of over 500 scientists from 34 countries in over 90 institutions

Through ongoing international symposia organized by ICAV, collaborations are developed, allowing scientists to leverage the respective strengths of their institutions.

In this way, ICAV harnesses the billions of dollars spent on public research every year by governments and foundations.

Harnessing the Power of International Scientific Collaboration for Drug Development

ICAV’s operating model draws on the great successes of the Canadian Network Centres of Excellence model. The Networks of Centres of Excellence are unique partnerships among universities, industry, government and not-for-profit organizations aimed at turning research and entrepreneurial talent into concrete economic and social benefits through innovation. These nation-wide, multidisciplinary and multi-sectoral research partnerships connect excellent research with industrial know-how and strategic investment. Because of Canada’s innate geographic and linguistic barriers, Canadian researchers have a great deal of experience leveraging results from complex partnerships spanning languages, time zones and institutional barriers.

ICAV’s unique approach expands this expertise to the international scene. Motivated leading investigators are provided with funding for targeted ICAV programs through trainee support and supplies that supplement their existing resources. Through international conferences, synergies are identified between scientists and collaborations are developed. The outcome is promising lead candidates that are incorporated into the ICAV drug development pipeline. Academic labs with specific expertise are engaged as core facilities, eliminating the need for ICAV to build physical infrastructure and helping to significantly reduce costs.